UBS Group
OBX icon

UBS Group’s Obsidian Therapeutics OBX Stock Holding History

UBS Group’s Portfolio OBX Stock Details OBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.74M Buy
+199,207
New +$3.89M ﹤0.01% 4743

Other funds holding OBX

Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Revelation Capital Management
Revelation Capital Management Sausalito, California $8.01M AUM 49.3% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return
Danske Bank
Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

UBS Group's OBX Position: Q3 2026 in Review

UBS Group opened a new position in Obsidian Therapeutics (OBX) in Q3 2026: 199,207 shares worth $2.74M. The stake represents ﹤0.01% of the portfolio and ranks #4743 among its holdings.

11 funds tracked by Wall St. Rank hold OBX as of Q3 2026.

  • UBS Group held 199,207 shares of Obsidian Therapeutics worth $2.74M as of Q3 2026.
  • Obsidian Therapeutics was a new UBS Group position in Q3 2026.
  • Obsidian Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #4743 holding.
  • 11 funds tracked by Wall St. Rank held Obsidian Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.